Tamara Jansen on Questions Passed as Orders for Returns

With regard to the transfer of Ebola and Henipah viruses from the National Microbiology Laboratory (NML) to persons, laboratories, and institutions in China: (a) who in China requested the transfer; (b) other than the Wuhan Institute of Virology (WIV), which laboratories in China requested the transfer; (c) for the answers in (a) and (b) which are affiliated with the military of China; (d) on what date was the WIV’s request for the transfer received by the NML; (e) what scientific research was proposed, or what other scientific rationale was put forth, by the WIV or the NML scientists to justify the transfer of Ebola and Henipah viruses; (f) what materials were authorized for transfer pursuant to Transfer Authorization NML-TA-18-0480, dated October 29, 2018; (g) did the NML receive payment of $75, per its commercial invoice of March 27, 2019, for the transfer, and on what date was payment received; (h) what consideration or compensation was received from China in exchange for providing this material, broken down by amount or details of the consideration or compensation received by each recipient organization; (i) has the government requested China to destroy or return the viruses and, if not, why; (j) did Canada include, as a term of the transfer, a prohibition on the WIV further transferring the viruses with others inside or outside China, except with Canada’s consent; (k) what due diligence did the NML perform to ensure that the WIF and other institutions referred to in (b) would not make use of the transferred viruses for military research or uses; (l) what inspections or audits did the NML perform of the WIV and other institutions referred to in (b) to ensure that they were able to handle the transferred viruses safely and without diversion to military research or uses; (m) what were the findings of the inspections or audits referred to in (l), in summary; (n) after the transfer, what follow-up has Canada conducted with the institutions referred to in (b) to ensure that the only research being performed with the transferred viruses is that which was disclosed at the time of the request for the transfer; (o) what intellectual property protections did Canada set in place before sending the transferred viruses to the persons and institutions referred to in (a) and (b); (p) of the Ebola virus strains sent to the WIV, what percentages of the NML’s total Ebola collection and Ebola collection authorized for sharing is represented by the material transferred; (q) other than the study entitled “Equine-Origin Immunoglobulin Fragments Protect Nonhuman Primates from Ebola Virus Disease”, which other published or unpublished studies did the NML scientists perform with scientists affiliated with the military of China; (r) which other studies are the NML scientists currently performing with scientists affiliated with the WIV, China’s Academy of Military Medical Sciences, or other parts of China’s military establishment; (s) what is the reason that Anders Leung of the NML attempted to send the transferred viruses in incorrect packaging (type PI650), and only changed its packaging to the correct standard (type PI620) after being questioned by the Chinese on February 20, 2019; (t) has the NML conducted an audit of the error of using unsafe packaging to transfer the viruses, and what in summary were its conclusions; (u) what is the reason that Allan Lau and Heidi Wood of the NML wrote on March 28, 2019, that they were “really hoping that this [the transferred viruses] goes through Vancouver” instead of Toronto on Air Canada, and “Fingers crossed!” for this specific routing; (v) what is the complete flight itinerary, including airlines and connecting airports, for the transfer; (w) were all airlines and airports on the flight itinerary informed by the NML that Ebola and Henipah viruses would be in their custody; (x) with reference to the email of Marie Gharib of the NML on March 27, 2019, other than Ebola and Henipah viruses, which other pathogens were requested by the WIV; (y) since the date of the request for transfer, other than Ebola and Henipah viruses, which other pathogens has the NML transferred or sought to transfer to the WIV; (z) did the NML inform Canada’s security establishment, including the RCMP, the Canadian Security Intelligence Service, the Communications Security Establishment, or other such entity, of the transfer before it occurred, and, if not, why not; (aa) what is the reason that the Public Health Agency of Canada (PHAC) redacted the name of the transfer recipient from documents disclosed to the Canadian Broadcasting Corporation (CBC) under the Access to Information Act, when the PHAC later willingly disclosed that information to the CBC; (bb) does Canada have any policy prohibiting the export of risk group 3 and 4 pathogens to countries, such as China, that conduct gain-of-function experiments, and in summary what is that policy; (cc) if Canada does not have any policy referred to in (bb), why not; (dd) what is the reason that did the NML or individual employees sought and obtained no permits or authorizations under the Human Pathogens and Toxins Act, the Transportation of Dangerous Goods Act, the Export Control Act, or related legislation prior to the transfer; (ee) what legal controls prevent the NML or other government laboratories sending group 3 or 4 pathogens to laboratories associated with foreign militaries or laboratories that conduct gain-of-function experiments; (ff) with respect to the September 14, 2018, email of Matthew Gilmour, in which he writes that “no certifications [were] provided [by the WIV], they simply cite they have them”, why did the NML proceed to transfer Ebola and Henipah viruses without proof of certification to handle them safely; and (gg) with respect to the September 14, 2018, email of Matthew Gilmour, in which he asked “Are there materials that [WIV] have that we would benefit from receiving? Other VHF? High path flu?”, did the NML request these or any other materials in exchange for the transfer, and did the NML receive them?